CN101610759A - 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用 - Google Patents

由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用 Download PDF

Info

Publication number
CN101610759A
CN101610759A CNA2007800459379A CN200780045937A CN101610759A CN 101610759 A CN101610759 A CN 101610759A CN A2007800459379 A CNA2007800459379 A CN A2007800459379A CN 200780045937 A CN200780045937 A CN 200780045937A CN 101610759 A CN101610759 A CN 101610759A
Authority
CN
China
Prior art keywords
peptide
nanoparticles
hydrophobic agents
nano
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800459379A
Other languages
English (en)
Chinese (zh)
Inventor
娜佳·I·塔拉索夫
谢尔盖·G·塔拉索夫
克里斯托弗·J·米海达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN101610759A publication Critical patent/CN101610759A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA2007800459379A 2006-11-07 2007-11-06 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用 Pending CN101610759A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86466506P 2006-11-07 2006-11-07
US60/864,665 2006-11-07

Publications (1)

Publication Number Publication Date
CN101610759A true CN101610759A (zh) 2009-12-23

Family

ID=39365311

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800459379A Pending CN101610759A (zh) 2006-11-07 2007-11-06 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用

Country Status (9)

Country Link
US (1) US9326950B2 (cg-RX-API-DMAC7.html)
EP (1) EP2086521A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010509241A (cg-RX-API-DMAC7.html)
CN (1) CN101610759A (cg-RX-API-DMAC7.html)
AU (1) AU2007316416A1 (cg-RX-API-DMAC7.html)
CA (1) CA2668638A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ576769A (cg-RX-API-DMAC7.html)
WO (1) WO2008058125A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200903125B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602856A (zh) * 2015-12-18 2018-09-28 康斯乔最高科学研究公司 一种包括低聚甘氨酸自组装体和纳米线的材料

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101610759A (zh) * 2006-11-07 2009-12-23 美国政府卫生与公共服务部 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用
WO2012162628A2 (en) 2011-05-25 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of ras oncoproteins
US9180203B2 (en) 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
WO2019018572A1 (en) * 2017-07-18 2019-01-24 Duke University COMPOSITIONS AND METHODS COMPRISING SELF-ASSEMBLY PEPTIDE-POLYMER NANOFIBERS FOR SUBLINGUAL IMMUNIZATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187775B1 (en) 1996-04-12 2001-02-13 The United States Of America As Represented By The Department Of Health And Human Services Acridone-derived compounds useful as antineoplastic and antiretroviral agents
US7105488B1 (en) 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
WO1999043711A1 (en) 1998-02-27 1999-09-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services G protein-coupled receptor antagonists
US7517849B1 (en) * 1999-11-18 2009-04-14 The United States Of America As Represented By The Secretary Of Health And Human Services Inhibition of ABC transporters by transmembrane domain analogs
ATE250603T1 (de) 2000-03-07 2003-10-15 Us Gov Health & Human Serv 1,8-naphthalimid imidazo(4,5,1-de)acridone mit antitumorwirkung
AU2001275423B2 (en) * 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
AU2002240201A1 (en) * 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2006010083A2 (en) * 2004-07-08 2006-01-26 Molecular Therapeutics, Inc. Biodegradable nanoparticles
CN101610759A (zh) * 2006-11-07 2009-12-23 美国政府卫生与公共服务部 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602856A (zh) * 2015-12-18 2018-09-28 康斯乔最高科学研究公司 一种包括低聚甘氨酸自组装体和纳米线的材料

Also Published As

Publication number Publication date
AU2007316416A1 (en) 2008-05-15
NZ576769A (en) 2012-01-12
EP2086521A2 (en) 2009-08-12
ZA200903125B (en) 2010-05-26
US20100034896A1 (en) 2010-02-11
WO2008058125A3 (en) 2008-10-16
JP2010509241A (ja) 2010-03-25
WO2008058125A2 (en) 2008-05-15
CA2668638A1 (en) 2008-05-15
US9326950B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
AU2021200135B2 (en) Liposome compositions and methods of use thereof
Saad et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
Xiao et al. “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo
Xu et al. Smart and hyper-fast responsive polyprodrug nanoplatform for targeted cancer therapy
Accardo et al. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs
M. Leite et al. Peptide self-assemblies for drug delivery
Wang et al. Zwitterionic Janus Dendrimer with distinct functional disparity for enhanced protein delivery
Houdaihed et al. Dual-targeted delivery of nanoparticles encapsulating paclitaxel and everolimus: A novel strategy to overcome breast cancer receptor heterogeneity
EP3405429B1 (en) Formation of functionalized nanoparticles by supramolecular co-assembly
CN105476975B (zh) 主动靶向型抗脑肿瘤药物及其制备方法
US9326950B2 (en) Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
CN103656650B (zh) 一种pH敏感的脑部肿瘤双级靶向纳米递药系统及制备方法和应用
Ruan et al. Stapled RAP12 peptide ligand of LRP1 for micelles-based multifunctional glioma-targeted drug delivery
WO2017063542A1 (zh) 稳定化a7r多肽及其在构建肿瘤靶向诊治递药系统中的用途
WO2018049155A1 (en) Compositions comprising polymeric nanoparticles and mcl-1 antagonists
CN106924731A (zh) 一种基于光动力疗法和化学疗法的联合肿瘤靶向治疗系统
US20190290726A1 (en) Protein polymer fusions for subcutaneous delivery of small molecules
Tong et al. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022, 14, 1036
Tesauro et al. Peptide-Based Drug Delivery Systems: Future Challenges, Perspectives, and Opportunities in Nanomedicine
PHUOC Development of multi-functionalized polymeric carriers for delivery of anticancer drug combinations
Ariani A Small Peptide Increases Drug Delivery in Human Melanoma Cells
Parent et al. NEMANY A. HANAFY
TW201018487A (en) Peptide ligand directed drug delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20091223

C20 Patent right or utility model deemed to be abandoned or is abandoned